Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EOGNYSEAMERICAN:SYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOGEOG Resources$119.77-2.7%$115.89$102.52▼$138.18$67.21B0.763.41 million shs3.69 million shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOGEOG Resources-3.80%+0.12%+5.13%+14.29%-4.14%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEOGEOG Resources4.5431 of 5 stars3.32.03.30.23.42.51.9SYNSynthetic BiologicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOGEOG Resources 2.52Moderate Buy$139.4816.45% UpsideSYNSynthetic Biologics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest UOG, SENX, SYN, and EOG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/22/2025EOGEOG ResourcesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/20/2025EOGEOG ResourcesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$145.006/17/2025EOGEOG ResourcesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$137.006/16/2025EOGEOG ResourcesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$146.00 ➝ $148.006/13/2025EOGEOG ResourcesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$144.00 ➝ $148.006/3/2025EOGEOG ResourcesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$135.00 ➝ $140.006/2/2025EOGEOG ResourcesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$137.00 ➝ $140.006/2/2025EOGEOG ResourcesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$148.00 ➝ $158.006/2/2025EOGEOG ResourcesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$132.00 ➝ $135.005/23/2025EOGEOG ResourcesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$125.00 ➝ $124.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOGEOG Resources$23.70B2.76$18.54 per share6.46$52.18 per share2.30SYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOGEOG Resources$6.40B$10.7811.1110.389.9426.14%22.35%14.17%7/30/2025 (Estimated)SYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ALatest UOG, SENX, SYN, and EOG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025EOGEOG Resources$2.75$2.87+$0.12$2.65$5.92 billion$5.84 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEOGEOG Resources$3.903.26%N/A36.18%8 YearsSYNSynthetic BiologicsN/AN/AN/AN/AN/ALatest UOG, SENX, SYN, and EOG DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/2/2025EOGEOG Resourcesquarterly$1.023.7%10/17/202510/17/202510/31/20255/1/2025EOGEOG Resourcesquarterly$0.97503.49%7/17/20257/17/20257/31/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOGEOG Resources0.121.871.71SYNSynthetic BiologicsN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOGEOG Resources89.91%SYNSynthetic Biologics74.38%Insider OwnershipCompanyInsider OwnershipEOGEOG Resources0.13%SYNSynthetic Biologics2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOGEOG Resources3,150545.79 million545.08 millionOptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableUOG, SENX, SYN, and EOG HeadlinesRecent News About These CompaniesSynthetic Dyes Present in 19 Percent of U.S. Food ProductsJuly 4, 2025 | msn.comFlexiteek Expands Synthetic Decking Line with New Tritone FinishJuly 3, 2025 | msn.comControversial ‘Synthetic Human Genome Project’ Spurs Debate Over Ethics of Building Human DNA from ScratchJuly 2, 2025 | thedebrief.orgTOn The Punt: Gilbert Gardiner's tips for Ballarat Synthetic on TuesdayJuly 2, 2025 | punters.com.auPSynthetic data, real results: Rewiring industrial inspection to work with AIJuly 1, 2025 | imveurope.comIUK launches bold Synthetic Human Genome Project: Can human DNA be built from scratch?June 27, 2025 | indiatvnews.comIAstroTurf Secures Historic Partnership as Official Synthetic Turf of Major League BaseballJune 27, 2025 | sfexaminer.comSSynthetic DNA research could lead to the creation of artificial life, Irish professor saysJune 27, 2025 | independent.ieIWhich mesh is best? Outcomes for abdominal ventral hernia repair patients projected by new research modelJune 25, 2025 | medicaldialogues.inMEULAR Updates Recommendations for Managing Rheumatoid ArthritisJune 20, 2025 | medscape.comMBenefits of early biologic treatment in psoriatic arthritis examined in studiesJune 12, 2025 | medicalxpress.comMWhich mesh is best? New research model projects outcomes for abdominal ventral hernia repair patientsJune 4, 2025 | msn.comBioNext: Generics to biologics, India’s moment to leadMay 26, 2025 | msn.comBiologics, Targeted Therapies Best for Acute PsA DactylitisMay 21, 2025 | medscape.comMInfection Patterns Matter in Selection of Advanced Therapies for Inflammatory ArthritisMay 16, 2025 | medscape.comMAnsa Biotechnologies Rolls Out Early Access Program for Long, Complex Synthetic DNA OrdersMay 11, 2025 | genengnews.comGMaxim Group Downgrades Theriva Biologics (TOVX)May 9, 2025 | msn.comAI and Machine Learning as Transformative BioToolsMay 7, 2025 | genengnews.comGCytiva and Asimov collaborate on next generation cell line design and process developmentApril 30, 2025 | pharmiweb.comPCytiva and Asimov Collaborate on NextGen Cell Line Design and Process DevelopmentApril 29, 2025 | genengnews.comGNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeSynopsys Stock Falls on China Ban, But Long-Term Outlook HoldsBy Leo Miller | June 14, 2025View Synopsys Stock Falls on China Ban, But Long-Term Outlook HoldsUOG, SENX, SYN, and EOG Company DescriptionsEOG Resources NYSE:EOG$119.77 -3.38 (-2.74%) Closing price 07/7/2025 03:59 PM EasternExtended Trading$119.20 -0.58 (-0.48%) As of 07/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EOG Resources, Inc., together with its subsidiaries, explores for, develops, produces, and markets crude oil, natural gas liquids, and natural gas primarily in producing basins in the United States, the Republic of Trinidad and Tobago and internationally. The company was formerly known as Enron Oil & Gas Company. EOG Resources, Inc. was incorporated in 1985 and is headquartered in Houston, Texas.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
